Cargando…

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors

Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the livers of patients without a history of alcohol abuse. It is classified as either simple steatosis (nonalcoholic fatty liver) or nonalcoholic steatohepatitis (NASH), which can progress to liver cirrhosis a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Yoshihisa, Dungubat, Erdenetsogt, Kusano, Hiroyuki, Fukusato, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604511/ https://www.ncbi.nlm.nih.gov/pubmed/37893134 http://dx.doi.org/10.3390/biomedicines11102761

Ejemplares similares

Application of Immunohistochemistry in the Pathological Diagnosis of Liver Tumors
por: Takahashi, Yoshihisa, et al.
Publicado: (2021)

Age-dependent sex difference of non-alcoholic fatty liver disease in TSOD and db/db mice
por: Dungubat, Erdenetsogt, et al.
Publicado: (2022)

Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet
por: Dungubat, Erdenetsogt, et al.
Publicado: (2020)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
por: Eskridge, Wayne, et al.
Publicado: (2023)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
por: Staufer, Katharina, et al.
Publicado: (2023)

The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
por: Paklar, Natasa, et al.
Publicado: (2023)

Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
por: Platek, Anna E., et al.
Publicado: (2023)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
por: Chan, Wah-Kheong, et al.
Publicado: (2023)

Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs
por: Zhu, Baoqiang, et al.
Publicado: (2023)

An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
por: Kendall, Timothy J., et al.
Publicado: (2023)

Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
por: Al-Shargi, Amani, et al.
Publicado: (2023)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach
por: Vesković, Milena, et al.
Publicado: (2023)

The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
por: Backer, Sean, et al.
Publicado: (2023)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
por: Kim, Gi-Ae, et al.
Publicado: (2023)

The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
por: Huang, Yunqian, et al.
Publicado: (2023)

Hepatic Gene Expression Profiles Differentiate Steatotic and Non-steatotic Grafts in Liver Transplant Recipients
por: Šeda, Ondrej, et al.
Publicado: (2019)

The impact of cortisol in steatotic and non‐steatotic liver surgery
por: Cornide‐Petronio, María Eugenia, et al.
Publicado: (2017)

Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES
por: Wu, Yanrui, et al.
Publicado: (2023)

Mitochondrial Pyruvate Carrier Inhibition Attenuates Hepatic Stellate Cell Activation and Liver Injury in a Mouse Model of Metabolic Dysfunction-associated Steatotic Liver Disease
por: Habibi, Mohammad, et al.
Publicado: (2023)

FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease
por: Arvaniti, Pinelopi, et al.
Publicado: (2023)

Frequency of Hepatic Metastatic Disease in Patients with Stage IV Breast Cancer Is Similar for Steatotic and Non-Steatotic Livers
por: Haq, Adeel, et al.
Publicado: (2023)

Association between the peripheral neutrophil-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes
por: Zhu, Nan, et al.
Publicado: (2023)

Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
por: Moon, Joon Ho, et al.
Publicado: (2023)

Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
por: Lai, Jiaming, et al.
Publicado: (2023)

Embracing the principles of practice transfer to get the word out on the new metabolic dysfunction-associated steatotic liver disease nomenclature
por: Carr, Rotonya M.
Publicado: (2023)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
por: Nagai, Koki, et al.
Publicado: (2023)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
por: Yeh, Ming-Lun, et al.
Publicado: (2023)

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy
por: Kjeldsen, Sasha A.S., et al.
Publicado: (2023)

Mitogen Activated Protein Kinases in Steatotic and Non-Steatotic Livers Submitted to Ischemia-Reperfusion
por: Jiménez-Castro, Mónica B., et al.
Publicado: (2019)

Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts
por: Da, Ben L, et al.
Publicado: (2022)

Personalized Risk Assessment of Hepatic Fibrosis after Cholecystectomy in Metabolic-Associated Steatotic Liver Disease: A Machine Learning Approach
por: Suárez, Miguel, et al.
Publicado: (2023)

The role of MLKL in Hepatic Ischemia-Reperfusion Injury of Alcoholic Steatotic Livers
por: Chen, Hao, et al.
Publicado: (2022)

Role of Dietary Nutritional Treatment on Hepatic and Intestinal Damage in Transplantation with Steatotic and Non-Steatotic Liver Grafts from Brain Dead Donors
por: Micó-Carnero, Marc, et al.
Publicado: (2021)

The Role of Neuregulin-1 in Steatotic and Non-Steatotic Liver Transplantation from Brain-Dead Donors
por: Micó-Carnero, Marc, et al.
Publicado: (2022)

Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease
por: van Dijk, A. M., et al.
Publicado: (2023)

Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population
por: Dalbeni, Andrea, et al.
Publicado: (2023)

The Role of GLP1 in Rat Steatotic and Non-Steatotic Liver Transplantation from Cardiocirculatory Death Donors
por: Avalos-de León, Cindy G., et al.
Publicado: (2019)

Hepatic connective tissue growth factor expression and regulation differ between non-steatotic and non-alcoholic steatotic livers from brain-dead donor
por: Yang, Dong-Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7njfvlkja6hkq0jjqmjsaev950